Polymyalgia Rheumatica News and Research

RSS

How do viral infections cause autoimmune diseases?

Researchers describe the pathological mechanisms of virus-induced autoimmune diseases.

28 Mar 2023

Integrated community care approach can offer solution to struggling rheumatology services, experts say

As patients wait up to a decade for the diagnosis of life-impacting rheumatic conditions, experts argue that ingrained pressures facing NHS rheumatology services can, and should, be eased with an integrated community care/secondary care approach, rather than a reliance on secondary care alone.

3 Aug 2022

Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease

Researchers investigated the longevity and intensity of the SARS-CoV-2 vaccine immune response in patients suffering from immune-mediated inflammatory diseases.

15 Apr 2022

Study investigates how vitamin D or omega fatty acids may affect rates of autoimmune diseases

Autoimmune diseases (AD) such as rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease and psoriasis, are a leading cause of morbidity and mortality as people age.

28 Jan 2022

Daily supplementation with vitamin D and fish oil may lower the risk of autoimmune disease

Taking daily vitamin D supplements - or a combination of vitamin D and omega-3 fish oil - appears to carry a lower risk of developing autoimmune disease, with a more pronounced effect after two years, finds a trial of older US adults published by The BMJ today.

27 Jan 2022

Gadolinium-enhanced MRI of shoulders helps predict recurrence of polymyalgia rheumatica

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, use of gadolinium-enhanced magnetic resonance imaging (MRI) in shoulders of patients with polymyalgia rheumatica may contribute to more accurate diagnosis and prediction of recurrence.

11 Nov 2019

Survey says half of people with rheumatoid disease struggle to pay for treatment

Rheumatoid disease encompasses inflammatory conditions that affect the joints, muscle, bones, and organs. A new study found that despite 90 of patients have health insurance, nearly 60 percent said that they are struggling to afford medication or treatment in the last year.

16 Sep 2019

Oral steroid use in patients with inflammatory diseases increases risk of infection

Oral steroid use in patients with the inflammatory diseases polymyalgia rheumatica and/or giant cell arteritis significantly increased the risk of infection, and the risk increased with higher doses, found a study in CMAJ.

24 Jun 2019

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Checkpoint inhibitor therapy is a form of cancer treatment immunotherapy currently under research. The therapy targets immune checkpoints, key regulators of the immune system that stimulate or inhibit its actions, which tumors can use to protect themselves from attacks by the immune system.

18 Jan 2019

Patients with rheumatologic disease can safely receive life-saving cancer immunotherapy

In the largest single-center study of patients with rheumatologic diseases who were prescribed modern cancer immunotherapy with what are called immune checkpoint inhibitors, only a minority of patients experienced a flare of their rheumatologic disease or immune-related side effects.

24 Jan 2018

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

A significant proportion of lung cancer patients also have autoimmune disease, which may make them unsuitable for increasingly popular immunotherapy treatments, a team of researchers at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center has found.

6 Jun 2016

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

A drug approved to treat rheumatoid arthritis, tocilizumab (Actemra, Genentech), is a potential new therapy for patients with polymyalgia rheumatica, according to an open-label, phase II study presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on November 10.

11 Nov 2015

ACR releases two new publications to improve treatment of polymyalgia rheumatica, gout

The American College of Rheumatology (ACR) has released two new publications - recommendations aimed at improving the treatment of patients with polymyalgia rheumatica (PMR), and new classification criteria for gout.

10 Sep 2015

Cranial ultrasound has greater sensitivity than temporal artery biopsy in diagnosis of GCA

A new study presented for the first time today at the European League Against Rheumatism Annual Congress (EULAR 2014), shows that cranial ultrasound has a greater sensitivity than temporal artery biopsy,* and a comparable specificity in the diagnosis of Giant Cell Arteritis (GCA).

13 Jun 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

Young, middle-aged fibromyalgia patients report poorer quality of life than older patients

It may seem counterintuitive, but young and middle-aged fibromyalgia patients report worse symptoms and poorer quality of life than older patients, a Mayo Clinic study shows.

28 Oct 2013

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Cardiovascular risk present across chronic rheumatic diseases

Patients across the spectrum of rheumatic diseases, not just those with rheumatoid arthritis, have a significantly increased prevalence of cardiovascular risk factors compared with the general population, the results of a Dutch study indicate.

6 Aug 2012

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Horizon Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).

26 Jul 2012

New ACR classification criteria for polymyalgia rheumatica

The American College of Rheumatology has released the first classification criteria for polymyalgia rheumatica - aimed at helping physicians identify patients with this condition, which occurs in persons aged 50 years or older who have recent onset of pain in the shoulders, neck and hips along with other inflammatory symptoms not explained by an alternate diagnosis.

2 Mar 2012